株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

硬変:世界の治験動向

Cirrhosis Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 324947
出版日 ページ情報 英文 493 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.54円で換算しております。
Back to Top
硬変:世界の治験動向 Cirrhosis Global Clinical Trials Review, H2, 2016
出版日: 2016年10月31日 ページ情報: 英文 493 Pages
概要

当レポートでは、硬変に関する臨床研究の最新動向について調査し、地域・進捗状況・フェーズ (相) ・募集状況別の実施件数や、代表的なスポンサー、開発中の治療薬の情報、世界各国の主要企業・機関での進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数:アジア太平洋地域
    • 上位5ヶ国における治験件数:欧州
    • 主要国における治験件数:北米
    • 上位5ヶ国における治験件数:中東/アフリカ地域
    • 上位5ヶ国における治験件数:中南米

G7諸国における治験件数:硬変治験件数の消化管疾患治験件数に対する比率

フェーズ(相)別治験件数:G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:硬変治験件数の消化管疾患治験件数に対する比率

フェーズ(相)別治験件数:E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別治験件数

有望なスポンサー

治験主要参加企業 - 硬変 治療薬

有望な薬剤

最新治験ニュース:硬変

治験プロファイルの基本情報

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3836CTIDB

GlobalData's clinical trial report, "Cirrhosis Global Clinical Trials Review, H2, 2016" provides an overview of Cirrhosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Cirrhosis to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Cirrhosis to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Cirrhosis Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Cirrhosis
      • Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting
      • Sep 19, 2016: Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy
      • Aug 02, 2016: Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Cirrhosis Therapeutics, Global, Clinical Trials by Region, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Cirrhosis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016*
  • Cirrhosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Cirrhosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Cirrhosis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016*
  • Cirrhosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Cirrhosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Cirrhosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Cirrhosis Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Cirrhosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Cirrhosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Cirrhosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Cirrhosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Cirrhosis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016*
  • Cirrhosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Cirrhosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Cirrhosis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016*
  • Cirrhosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Cirrhosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Cirrhosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top